Compugen (CGEN) H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Conference summary

Company overview and platform

• Focuses on immuno-oncology, pioneering computational discovery of novel drug targets using AI and machine learning.

• Two clinical-stage assets: COM-902 (TIGIT blocker) and COM-701 (PVRIG blocker), both fully owned.

• Unigen platform leverages a proprietary multi-omics tumor database, harmonized and queried using AI, including large language models.

• Platform validated by multiple first-in-class assets and partnerships with AstraZeneca, Gilead, Bayer, and Bristol Myers.

• Early pipeline includes several undisclosed immuno-oncology assets derived from Unigen.

Key partnerships and deal structures

• AstraZeneca partnership centers on COM-902, incorporated into Rilvegostomig, a TIGIT/PD-1 bispecific in multiple phase III trials.

• Rilvegostomig shows promising efficacy and safety, with phase III readouts expected by 2026–2027.

• AstraZeneca deal valued at $200 million, with $30 million received and up to $170 million in milestones plus mid-single-digit royalties on potential $5B+ sales.

• Gilead partnership for GS-0321 (IL-18 BP antibody) is an $850 million deal, with $90 million received to date and tiered royalties up to low double digits.

• Compugen leads phase I for GS-0321, with Gilead to take over in later stages.

Clinical pipeline and development plans

• COM-701 targets PVRIG, highly expressed in ovarian cancer, showing durable responses in platinum-resistant patients.

• Adaptive randomized platform trial for COM-701 to start in Q2 2025, with interim data expected in H2 2026.

• Success defined as a 3-month PFS improvement over placebo; options include accelerated approval, phase III, or combination studies.

• GS-0321 (IL-18 BP antibody) in phase I, with broad potential across solid tumors; expansion cohorts to be defined by early signals.

• Rilvegostomig phase III trials target non-small cell lung and gastrointestinal cancers, with combinations involving ADCs and chemotherapies.